Company news

RenovoRx, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer

December 20, 2023

RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting

December 18, 2023

RenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform

December 12, 2023

RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.

November 15, 2023

RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights

November 13, 2023

RenovoRx to Present at the ROTH MKM Healthcare Opportunities Conference on October 12, 2023

October 1, 2023

RenovoRx Reports Second Quarter 2023 Financial Results and Operational Highlights

August 16, 2023

RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference

July 30, 2023

RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform

July 19, 2023

RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP) Platform

July 19, 2023

RenovoRx Announces New Positive Interim Phase III Data Demonstrating RenovoGem™ Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer

June 28, 2023

RenovoRx Appoints Margaret A. Tempero, M.D., to Scientific Advisory Board

June 19, 2023

RenovoRx Reports First Quarter 2023 Financial Results and Operational Highlights

May 14, 2023

RenovoRx Sponsors Pancreatic Cancer Action Network’s PurpleStride® Event

April 30, 2023

RenovoRx Appoints Former Chief Medical Officer of Schering-Plough, Robert J. Spiegel, MD, FACP, to Board of Directors

April 26, 2023

RenovoRx Presenting Phase III Clinical Trial Interim Analysis Data of the TIGeR-PaC Study at American Association for Cancer Research Annual Meeting Underway in Orlando, Florida

April 13, 2023

RenovoRx Appoints Leesa Gentry as Senior Vice President of Clinical Operations

April 10, 2023

RenovoRx, Inc. Announces $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

March 29, 2023

RenovoRx Announces Positive New Data from Phase III Clinical Trial Interim Analysis: 60% Survival Benefit and Fewer Side Effects than Systemic Chemotherapy

March 29, 2023

RenovoRx Reports Full Year 2022 Financial Results and Achievement of Important Phase III Clinical Study Milestone

March 1, 2023

RenovoRx Announces Initial Results in Pharmacokinetic (PK) Substudy: Data on RenovoGem™ Supports Potential for RenovoTAMP® Therapy Platform to Increase Local Gemcitabine (Chemotherapy) Delivery and Decrease Side Effects of Pancreatic Cancer Treatment

January 17, 2023

RenovoRx Strengthens Intellectual Property (IP) Portfolio with Eighth US Patent

January 4, 2023

RenovoRx Announces Acceptance of Four Clinical Data Abstracts at the 2023 ASCO Gastrointestinal Cancers (ASCO GI) Symposium

December 14, 2022

RenovoRx Announces Presentations at the Advanced Interventional Management Symposium (AIMsymposium) Highlighting its Innovative RenovoTAMP® Therapy Platform for Targeted Treatment of Cancers

November 16, 2022

RenovoRx Reports Third Quarter 2022 Financial Results

November 13, 2022

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology (CIO) Highlighting its Innovative Therapy Platform for Targeted Treatment of Pancreatic Cancer

September 27, 2022

RenovoRx Appoints Angela Gill Nelms as Chief Operating Officer

September 18, 2022

RenovoRx Reports Second Quarter 2022 Financial Results

August 14, 2022

RenovoRx Appoints James Ahlers as Chief Financial Officer

July 18, 2022

RenovoRx Reports First Quarter 2022 Financial Results

May 15, 2022

RenovoRx Reports Full Year 2021 Financial Results

March 29, 2022

RenovoRx Announces Presentation at the 2022 SPECTRUM Conference Highlighting Its Innovative RenovoTAMP™ Therapy for Targeted Treatment of Cancer

January 18, 2022

RenovoRx Announces Third Quarter 2021 Financial Results

November 14, 2021

RenovoRx Announces Presentation of Final Data from RR2 Observational Registry Study at 2021 Pancreas Club Annual Meeting

November 10, 2021

RenovoRx Receives New 510(k) Clearance for its RenovoCath® Delivery System Designed for Targeted Treatment of Solid Tumors

September 6, 2021

← Newer news releases

Calls

The 5 newest of 6 calls. Every call is listed under its year.

Decks